ITCI250117C62500
- 0.00
- 0.000.00%
Intra-Cellular Therapies Newsroom
S&P 500 Futures Drop In Premarket Trading; Intra-Cellular Therapies, Avantor Lag
Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...
Intra-Cellular Therapies(ITCI.US) Officer Sells US$8.72 Million in Common Stock
$Intra-Cellular Therapies(ITCI.US)$ Officer Mates Sharon sold 102.7K shares of common stock on Dec 4, 5, 2024 at an average price of $84.9343 for a total value of $8.72 million.Source: Announcement
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Intra-Cellular Therapies Files Supplemental NDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder
Express News | Intra-Cellular Therapies Submits Supplemental New Drug Application (Snda) to FDA for Caplyta® (Lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100
RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87
Express News | Intra-Cellular Therapies Inc : UBS Raises Target Price to $87 From $79
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
US Manufacturing Index Rises To 43, Highest Since 2020
Intra-Cellular Therapies Insider Sold Shares Worth $3,692,100, According to a Recent SEC Filing
Intra-Cellular Therapies(ITCI.US) Officer Sells US$3.69 Million in Common Stock
$Intra-Cellular Therapies(ITCI.US)$ Officer Halstead Michael sold 41,583 shares of common stock on Nov 12, 13, 2024 at an average price of $88.79 for a total value of $3.69 million.Source:
Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 3.7 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $Intra-Cellular Therapies(ITCI.US)$ Officer Halstead Michael intends to sell 41,583 shares of its common stock on Nov 12, with a total market value of approximately $3.
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is Still On The Mark Following 26% Share Price Bounce
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%
Intra-Cellular Meets Main Goal in Late Stage Trial for Its Schizophrenia Treatment